The Dihydroartemisinin-Piperaquine (DP) Dose Impact Study Group found that the dihydroartemisinin-piperaquine demonstrates excellent efficacy in a wide range of transmission settings. However, treatment failure is associated with a lower dose of piperaquine, particularly in young children. This suggests potential to further optimise treatment regimens. The results of the Study Group were published in December 2013: The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data in PLoS Medicine.
In the final analysis 7,072 patients from 26 published studies conducted in 2004–2013 were included. These studies represent 70 per cent of the targeted published literature on DP. Of these patients 39.7% were from 12 studies conducted in Asia, 56.7% from 13 studies from Africa, and 3.6% from one study conducted in South America. The DP Dose Impact Study Group was formed in October 2011, with an open invitation to interested researchers with relevant data sets. A meeting of potential study group participants was held at the December 2011 ASTMH Annual Meeting to discuss the Study Group governance and publication policy. The study group closed December 2012.
Results from this study group provided evidence for the revised recommendations for optimal use of artemisinin combination therapies included in the updated WHO ‘Guidelines for the Treatment of Malaria' in June 2015. Download a presentation from the DP Dose Impact Study Group.